Radiation Oncology, Treatment Protocols
Lung, Lung - Non-Small Cell
Phase I Trial of Accelerated or Conventionally Fractionated Radiotherapy Combined with MEDI4736 (Durvalumab) in PD-L1 High Locally Advanced Non-Small Cell Lung Cancer (NSCLC) (ARCHON-1)
Effective January 22, 2020, LU004 has enrolled 6 patients onto the ACRT + MEDI4736 (durvalumab) arm and completed accrual to Cohort 1. The next 6 patients will be enrolled to the standard radiation + MEDI4736 (durvalumab) arm. After a total of 12 patients have been enrolled, the study will temporarily close to accrual in order to monitor the safety of these two regimens.